Transforming growth factor beta (TGF‐β), most often produced by immune cells and microglia, is a prominent therapeutic target in GBM and has been investigated both in preclinical and in clinical studies (Joseph et al., 2013). The gene discussed is TGFB1; the disease is glioblastoma.